NASDAQ:NURO - Neurometrix Stock Price, Forecast & News

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

Neurometrix's stock reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

Neurometrix Inc (NASDAQ:NURO) posted its quarterly earnings results on Thursday, October, 17th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The medical device company had revenue of $2.09 million for the quarter, compared to analysts' expectations of $3.94 million. Neurometrix had a negative return on equity of 65.19% and a negative net margin of 48.86%. View Neurometrix's Earnings History.

Neurometrix is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for Neurometrix.

Neurometrix will be holding an earnings conference call on Thursday, January 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

1 analysts have issued twelve-month price objectives for Neurometrix's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Neurometrix.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.

News coverage about NURO stock has trended extremely negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurometrix earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Neurometrix.

Neurometrix saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 59,300 shares, an increase of 20.0% from the December 15th total of 49,400 shares. Based on an average daily trading volume, of 130,900 shares, the short-interest ratio is currently 0.5 days. Currently, 6.2% of the company's stock are short sold. View Neurometrix's Current Options Chain.

Some companies that are related to Neurometrix include Obalon Therapeutics (OBLN), Atossa Genetics (ATOS), Avinger (AVGR), Hancock Jaffe Laboratories (HJLI), PlusTherapeuticsInc . (PSTV), Lianluo Smart (LLIT), Dynatronics (DYNT), Valeritas (VLRX), CELLECT BIOTECH/S (APOP), Encision (ECIA), Invivo Therapeutics (NVIV), AdvanSource Biomaterials Corpration (ASNB), Sintx Technologies (SINT), Cytocore (MDIT) and Nuvectra (NVTR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurometrix investors own include Merit Medical Systems (MMSI), NovaBay Pharmaceuticals (NBY), Rewalk Robotics (RWLK), Palatin Technologies (PTN), TransEnterix (TRXC), SLS International (SLS), OraSure Technologies (OSUR), 180 Degree Capital (TURN), Citigroup (C) and Advanced Micro Devices (AMD).

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NURO stock can currently be purchased for approximately $4.26.

Neurometrix has a market capitalization of $4.17 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe.View Additional Information About Neurometrix.

The official website for Neurometrix is http://www.neurometrix.com/.

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]